Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa

Group 1 - Biohaven Ltd. has completed enrollment in a Phase 2 proof-of-concept study for taldefgrobep alfa, targeting weight loss in obesity, with topline data expected in the second half of 2026 [1][6] - TD Cowen analyst Ken Cacciatore raised the price target for Biohaven Ltd. to $30 from $15, maintaining a Buy rating, based on positive data regarding the Kv7 mechanism of action in focal epilepsy [2] - Biohaven reported Q4 adjusted EPS of (90c), slightly better than the consensus estimate of (96c), with the CEO highlighting significant progress in advancing the company's pipeline [3] Group 2 - Biohaven Ltd. develops therapies across immunology, neuroscience, and oncology, indicating a diverse therapeutic focus [4]